)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
IRLAB Therapeutics
IRLAB Therapeutics (IRLAB) investor relations material
IRLAB Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary13 Nov, 2026
Executive summary
Strategic focus shifted from expanding the pipeline to business development, partnerships and monetizing existing assets; workforce reductions and a lower cost base are planned.
Q3 net sales were SEK 6.9m and operating loss SEK 12.9m; 9M net sales rose to SEK 52.7m while operating loss narrowed to SEK 18.9m.
A SEK 76.5m gross rights issue and overallotment strengthened liquidity, but the auditor highlighted material uncertainty about continuing as a going concern without further liquidity injections.
Financial highlights
9M total revenue was SEK 57.1m, including SEK 52.7m net sales: an Otsuka milestone of USD 3m (SEK 27.1m) and SEK 25.6m in service revenue.
Q3 net sales were SEK 6.9m vs SEK 18.8m YoY; 9M net sales were SEK 52.7m vs SEK 42.7m.
9M operating loss was SEK 18.9m vs SEK 71.5m; net loss was SEK 23.3m vs SEK 86.5m; EPS was -SEK 0.22 vs -SEK 1.42.
9M operating expenses fell to SEK 76.0m from SEK 119.8m, largely reflecting lower clinical activity and cost-saving measures; R&D costs were SEK 60.4m.
Cash and cash equivalents were SEK 90.6m at period-end vs SEK 110.1m a year earlier; 9M operating cash outflow was SEK 53.1m.
Outlook and guidance
Resources are being redirected toward business development, strategic partnerships and value creation from existing programs; further cost-saving measures and workforce reductions are planned.
Licensing and partnership discussions continue, but agreements are taking longer than anticipated and the likelihood of new partnership agreements in 2026 was reduced.
Linepemat LIFT-PD results are expected in mid-2027; IRL1117 preclinical safety and toxicology work and manufacturing scale-up are intended to support a future Phase I application.
Mesdopetam Phase III development requires funding through strategic partnerships or licensing; pirepemat work is focused on dose optimization and preparations for a future study.
IRL942 development pace was reduced; required preclinical regulatory safety and toxicology studies are not expected to be completed before 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IRLAB Therapeutics
- Phase IIb findings selected 7.5 mg twice daily as the Phase III dose.IRLAB
Study Update - Advancing late-stage Parkinson's pipeline with AI-driven discovery and active partnering efforts.IRLABABGSC Investor Days
- Robust clinical progress and strengthened cash position after an oversubscribed rights issue.IRLABQ2 2026
- Milestone revenue and strong financing drive profit and pipeline advancement.IRLABQ1 2026
- New patents and clinical progress offset by declining sales and negative equity.IRLABQ2 2025
- Strong clinical and financial progress, but future financing remains a key uncertainty.IRLABQ3 2024
- Clinical and financial progress achieved, but new funding is needed for future continuity.IRLABQ2 2024
- Regulatory and clinical advances drive pipeline progress, but financial risks persist.IRLABQ1 2025
- Advanced pipeline, improved financials, and key milestones, but funding risks persist.IRLABQ4 2024
Next IRLAB Therapeutics earnings date
Q4 202612 Feb, 2027
IRLAB Therapeutics
Next IRLAB Therapeutics earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
IRLAB Therapeutics AB is a research and development company developing drugs for the treatment of Parkinson's disease. IRLAB develops drugs that can stop or slow down the loss of neurons in the substantia nigra, where dopamine is produced. In Parkinson's disease, loss of these neurons leads to a gradual degeneration of the motor functions. These drugs will improve symptoms without dramatically increasing the risk of side effects.